Therapeutic Asset Ratings

502 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
azd8359 Metastatic Prostate Carcinoma	AstraZeneca	P1/2	CC (43)
Camizestrant Urinary Bladder Carcinoma	AstraZeneca	P1/2	CC (43)
Datopotamab Deruxtecan Urinary Bladder Carcinoma	AstraZeneca	P1/2	CC (43)
Palacaparib Metastatic Prostate Carcinoma	AstraZeneca	P1/2	CC (43)
T-Dxd Urinary Bladder Carcinoma	AstraZeneca	P1/2	CC (43)
AZ-14226229 Idiopathic Pulmonary Fibrosis	AstraZeneca	P1	CC (42)
azd7503 Metabolic Dysfunction-Associated Steatotic Liver Disease	AstraZeneca	P1	CC (42)
Doxycycline Healthy Participants	AstraZeneca	P1	CC (42)
PANITUMUMAB Healthy Participants	AstraZeneca	P1	CC (42)
REPAGLINIDE Healthy Participants	AstraZeneca	P1	CC (42)
Wellbutrin Healthy Participants	AstraZeneca	P1	CC (42)
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) Advanced Solid Malignancies	AstraZeneca	P1	CC (41)
Autologous, Engineered T Cells Targeting Tp53 R175H Other Solid Tumors	AstraZeneca	P1	CC (41)
AZD0240 KRAS G12D	AstraZeneca	P1	CC (41)
azd0240: autologous, engineered t cells targeting kras g12d KRAS G12D	AstraZeneca	P1	CC (41)
azd1390 Advanced Solid Malignancies	AstraZeneca	P1	CC (41)
azd9592 Head And Neck Neoplasm	AstraZeneca	P1	CC (41)
Calcium folinate pentahydrate Head and Neck Neoplasms	AstraZeneca	P1	CC (41)
Durvalumab Solid Tumours	AstraZeneca	P1	CC (41)
DYNAMOS Advanced Solid Malignancies	AstraZeneca	P1	CC (41)
FUROSEMIDE Advanced Solid Malignancies	AstraZeneca	P1	CC (41)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Solid Tumours	AstraZeneca	P1	CC (41)
Irinotecan Head and Neck Neoplasms	AstraZeneca	P1	CC (41)
Metformin Advanced Solid Malignancies	AstraZeneca	P1	CC (41)
NT-112 KRAS G12D	AstraZeneca	P1	CC (41)

Showing 326 to 350 of 502 assets

PreviousPage 14 of 21Next